BioStable Science & Engineering, Inc.

BioStable Science & Engineering, Inc.

BioStable Science & Engineering, Inc.

Date Founded



2621 Ridgepoint Drive SUITE 100 AUSTIN TX 78754

Type of Company


Employees (Worldwide)

11 - 50


Medical Products & Equipment
IT Consulting & Services
Medical Support Services
Hospitals & Patient Services
Holding Companies

Company Description

BioStable Science & Engineering, Inc. engagses in the develop of products for the treatment of cardiovascular disease. It covers areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution. The firm provides a competitive edge by minimizing time to market for cost effective medical devices that deliver improved clinical outcomes. The company was founded by Al Alan Beavan, Charles D. Griffin, Douglas Charles Frank, Don James, J. Scott Rankin and Rusty Phillips in 2008 and is headquartered in Austin, TX.

Executives & Employees


President & Chief Executive Officer

Controller & Human Resources Manager

Vice President, Operations

Vice President of Sales

Board of Directors

Co-Founder at SHVMS, LLC

President & Chief Executive Officer at Orlando Health, Inc.

Chairman, Chief Scientific Officer & Founder at Glenveigh Medical LLC

President & Chief Executive Officer at BioStable Science & Engineering, Inc.

Paths to BioStable Science & Engineering, Inc.
Potential Connections via
Relationship Science
BioStable Science & Engineering, Inc.
Recent Transactions
Details Hidden

BioStable Science & Engineering, Inc. raised money in a private placement transaction

Details Hidden

Solas Bioventures invests in life sciences companies located in the US. The firm targets the companies operating in the fields of biopharmaceuticals, medical devices, diagnostics, digital health technologies. It provides financing for early and development stage capital requirements.

Details Hidden

Rex Health Ventures (RHV) supports the discovery and development of new treatments, tools, products and services that foster innovation and positively impact the provision of healthcare. The seek to help companies and entrepreneurs bring their products and services into the healthcare market. The firm makes seed and early-stage investments. RHV will consider pre-revenue opportunities, but they generally prefer companies that have at least developed a prototype or beta product. The firm is particularly interested in investments in the following sectors: healthcare information technology, healthcare services, medical devices and BioPharma technologies. Initial investments range from $250,000 to $500,000 and total per company investments range from $500,000 to $2 million. RHV targets investments where there is a realistic possibility of exit within 5 to 7 years.

Details Hidden

Longmeadow invests in small- to mid-sized businesses with revenues between $2 million and $20 million, preferably located in New England. They look for companies with proven management (with capital invested in the business), operating profitability, clear competitive advantage and a unique skill or franchise.Longmeadow provides capital to support acquisitions and organic growth to overcome the challenges of rapid growth. They partner with existing management teams to sponsor buyouts, raising all required financing, structuring the deal and providing strategic discipline after closing. Longmeadow sponsors purchases of businesses, including negotiation of the transaction, recruiting additional management and providing strategic discipline after closing. They also provide capital for company ownership transitions to active management shareholders and liquidity to current ownership. Longmeadow invests in turnaround situations that have a limited set of issues such as a destructive capital structure, temporary market dislocations or a single operational challenge.Initial investments range from $500,000 to $2.5 million. With their investors and co-investors, Longmeadow can provide significantly larger amounts of risk capital. Transactions are structured as preferred stock and subordinated debt with equity features. They take a strong presence in the business but outright control is not required. Longmeadow expects a three to seven year time horizon.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by BioStable Science & Engineering, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of BioStable Science & Engineering, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and BioStable Science & Engineering, Inc..